Impact of Targeted Therapy on Cancer-Related Impairment

Active:	Yes
Cancer Type:	Leukemia	NCT ID:	NCT07638007
Trial Phases:	Phase I	Protocol IDs:	URCC-24060 (primary) URCC-24060 URCC-24060 NCI-2025-04174
Eligibility:	18 Years and older, Male and Female	Study Type:	Prevention
Study Sponsor:	University of Rochester NCORP Research Base
NCI Full Details:	http://clinicaltrials.gov/show/NCT07638007

Summary

This study examines whether there are differences in brain health or well-being in patients receiving TKI therapy for leukemia compared to individuals who do not receive TKI therapy.

Objectives

PRIMARY OBJECTIVE:
I. Characterize differences in subjective CRCI longitudinally among patients receiving TKIs for CML or CLL.

OUTLINE: This is an observational study. Participants are assigned to 1 of 2 groups.

GROUP I: TKI recipients complete surveys, undergo cognitive assessments, undergo saliva sample collection, and have their medical records reviewed on study.

GROUP II: Cancer-free individuals complete surveys, undergo cognitive assessments, undergo saliva sample collection, and have their medical records reviewed on study.

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.